These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39161974)

  • 1. Emerging Role of Functional Magnetic Resonance Spectroscopy (MRS) to Monitor Response to Kinase Inhibitors in Cancer.
    Nath K; Gupta PK; Wasik MA
    Adv Cancer Res Clin Imaging; 2024; 4(3):. PubMed ID: 39161974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition.
    Nath K; Gupta PK; Basappa J; Wang S; Sen N; Lobello C; Tomar JS; Shestov AA; Orlovskiy S; Arias-Mendoza F; Rauert-Wunderlich H; Nelson DS; Glickson JD; Wasik MA
    J Transl Med; 2024 Jul; 22(1):622. PubMed ID: 38965536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
    Lee SC; Shestov AA; Guo L; Zhang Q; Roman JC; Liu X; Wang HY; Pickup S; Nath K; Lu P; Hofbauer S; Mesaros C; Wang YL; Nelson DS; Schuster SJ; Blair IA; Glickson JD; Wasik MA
    Mol Cancer Res; 2019 Jun; 17(6):1365-1377. PubMed ID: 30862686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
    Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
    Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
    Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
    Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
    Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
    Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
    Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.
    Lu Z; Wang Z; Tu Z; Liu H
    Front Pharmacol; 2022; 13():864194. PubMed ID: 35721157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.
    Burger JA
    Curr Hematol Malig Rep; 2014 Mar; 9(1):44-9. PubMed ID: 24357428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
    Dostálová H; Kryštof V
    Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma.
    Li J; Yu H; Wang X; Ye Y; Fang W; Ding N; Mi L; Ping L; Wang X; Song Y; Zhu J
    Cancer Control; 2022; 29():10732748221143881. PubMed ID: 36519740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.